Nektar Therapeutics (NKTR) and partner AstraZeneca (AZN) announced after the close Thursday that the majority of FDAQ Anesthetic and Analgesic Drug Products Advisory Committee members voted that the FDA should not require cardiovascular outcomes trials for the peripherally-acting mu-opioid receptor antagonist class of drugs. This includes MOVANTIKTM, an investigational treatment for opioid-induced constipation for patients with chronic non-cancer pain.
Nektar Therapeutics was range-bound throughout Thursday's session and finished with a gain of 0.30 at $12.54. The stock is now up 1.34 on 96K shares after the bell.
For comments and feedback: editorial@rttnews.com